– Published the differentiated mechanism of action of EDG-7500 that targets the regulatory light chain –
– Phase 3 trial for EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) on track to initiate by year-end 2026 –
– Dosed first patient in Phase 2 EQUINOX-HFpEF trial of EDG-15400 in heart failure with preserved ejection fraction (HFpEF) –
BOULDER, Colo., Nov. 4, 2026 — Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage cardiovascular biopharmaceutical company, today reported financial results for the third quarter of 2026 and recent business highlights.
“Our third quarter reflects continued execution across both cardiovascular programs,” said Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise. “In HCM, positive CIRRUS-HCM Part D results and our JCI Insight publication reinforce the differentiated profile of EDG-7500, and we expect to initiate our Phase 3 trial by year-end 2026.